08:00 , Dec 6, 2010 |  BC Week In Review  |  Clinical News

AB Therapeutics preclinical data

In mouse models of NSCLC, ABTL0812 and ABTL1014 each reduced tumor growth by 70% vs. both placebo and Taxotere docetaxel. The company plans to start Phase I testing with 1 of the undisclosed...
08:00 , Dec 6, 2010 |  BC Week In Review  |  Clinical News

AB Therapeutics preclinical data

In mouse models of NSCLC, ABTL0812 and ABTL1014 each reduced tumor growth by 70% vs. both placebo and Taxotere docetaxel. The company plans to start Phase I testing with 1 of the undisclosed...